Crizotinib-associated renal cyst development may be associated with prolonged progression-free survival in patients with ALK-positive non-small-cell lung cancer: Case report and review of the literature

Nathaniel E. Wiest, Katherine S. Tzou, Matthew T. Olson, Steven M. Herchko, Essa M. Bajalia, David D. Thiel, Yanyan Lou, Yujie Zhao, Rami Manochakian

Research output: Contribution to journalArticlepeer-review

Abstract

Non-small cell lung cancer patients with anaplastic lymphoma kinase or c-ros oncogene 1 mutations who are treated with the tyrosine kinase inhibitor crizotinib rarely develop crizotinib-associated renal cysts (CARCs). Here, we present a case report and review of the literature supporting the hypothesis that CARCs may correlate positively with progression-free survival.

Original languageEnglish (US)
Article numbere04278
JournalClinical Case Reports
Volume9
Issue number6
DOIs
StatePublished - Jun 2021

Keywords

  • ALK positive
  • crizotinib
  • non-small-cell lung cancer
  • progression-free survival
  • renal cysts

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint

Dive into the research topics of 'Crizotinib-associated renal cyst development may be associated with prolonged progression-free survival in patients with ALK-positive non-small-cell lung cancer: Case report and review of the literature'. Together they form a unique fingerprint.

Cite this